Former Aptose Biosciences Officer Disposes All Equity Holdings Following Acquisition

This Form 4 filing reports that Rafael Bejar, former Senior Vice President and Chief Medical Officer of Aptose Biosciences Inc., disposed of all his equity holdings in the company on June 30, 2026. The disposals occurred as part of Hammi Pharmaceuticals Co. Inc.'s acquisition of all outstanding shares of Aptose Biosciences at C$2.41 per share (approximately US$1.72 per share). Bejar disposed of 244 common shares and six separate option grants totaling 1,598,000 options with various exercise prices ranging from $0.66 to $6.91. The options included employee stock options, performance stock options, and employee option grants, all of which were disposed of pursuant to the acquisition agreement. Following these transactions, Bejar holds zero shares and zero options in the company. The filing notes that option quantities and exercise prices were adjusted for the company's previous reverse stock splits in 2023 and 2025.